Cabantchik Zvi Ioav
Department of Biological Chemistry, Institute of Life Sciences, Hebrew University of Jerusalem Jerusalem, Israel.
Front Pharmacol. 2014 Mar 13;5:45. doi: 10.3389/fphar.2014.00045. eCollection 2014.
In living systems iron appears predominantly associated with proteins, but can also be detected in forms referred as labile iron, which denotes the combined redox properties of iron and its amenability to exchange between ligands, including chelators. The labile cell iron (LCI) composition varies with metal concentration and substances with chelating groups but also with pH and the medium redox potential. Although physiologically in the lower μM range, LCI plays a key role in cell iron economy as cross-roads of metabolic pathways. LCI levels are continually regulated by an iron-responsive machinery that balances iron uptake versus deposition into ferritin. However, LCI rises aberrantly in some cell types due to faulty cell utilization pathways or infiltration by pathological iron forms that are found in hemosiderotic plasma. As LCI attains pathological levels, it can catalyze reactive O species (ROS) formation that, at particular threshold, can surpass cellular anti-oxidant capacities and seriously damage its constituents. While in normal plasma and interstitial fluids, virtually all iron is securely carried by circulating transferrin (Tf; that renders iron essentially non-labile), in systemic iron overload (IO), the total plasma iron binding capacity is often surpassed by a massive iron influx from hyperabsorptive gut or from erythrocyte overburdened spleen and/or liver. As plasma Tf approaches iron saturation, labile plasma iron (LPI) emerges in forms that can infiltrate cells by unregulated routes and raise LCI to toxic levels. Despite the limited knowledge available on LPI speciation in different types and degrees of IO, LPI measurements can be and are in fact used for identifying systemic IO and for initiating/adjusting chelation regimens to attain full-day LPI protection. A recent application of labile iron assay is the detection of labile components in intravenous iron formulations per se as well as in plasma (LPI) following parenteral iron administration.
在生命系统中,铁主要与蛋白质结合,但也能以所谓的不稳定铁形式被检测到,不稳定铁表示铁的综合氧化还原特性及其在包括螯合剂在内的配体之间进行交换的能力。不稳定细胞铁(LCI)的组成随金属浓度、具有螯合基团的物质而变化,也随pH值和介质氧化还原电位而变化。尽管在生理状态下LCI处于较低的微摩尔范围内,但它作为代谢途径的交叉点,在细胞铁代谢中起着关键作用。LCI水平通过一种铁反应机制持续调节,该机制平衡铁的摄取与铁蛋白中的沉积。然而,由于细胞利用途径错误或含铁血黄素血浆中存在的病理性铁形式的浸润,LCI在某些细胞类型中异常升高。当LCI达到病理水平时,它可以催化活性氧(ROS)的形成,在特定阈值下,ROS会超过细胞抗氧化能力并严重损害细胞成分。在正常血浆和组织液中,几乎所有的铁都由循环转铁蛋白(Tf;使铁基本上不具有活性)安全携带,而在全身性铁过载(IO)中,来自高吸收性肠道或负担过重的红细胞脾脏和/或肝脏的大量铁流入常常超过血浆总铁结合能力。随着血浆Tf接近铁饱和,不稳定血浆铁(LPI)以能够通过不受调节的途径渗入细胞并将LCI提高到有毒水平的形式出现。尽管关于不同类型和程度的IO中LPI形态的知识有限,但LPI测量可以而且实际上被用于识别全身性IO以及启动/调整螯合方案以实现全天的LPI保护。不稳定铁测定的一个最新应用是检测静脉铁制剂本身以及胃肠外铁给药后血浆中的不稳定成分(LPI)。